Catalyst Biosciences Inc (CBIO) Sees Strong Trading Volume
Catalyst Biosciences Inc (NASDAQ:CBIO) shares saw unusually-strong trading volume on Wednesday . Approximately 8,714,744 shares were traded during trading, an increase of 5,876% from the previous session’s volume of 145,834 shares.The stock last traded at $3.78 and had previously closed at $3.39.
Several analysts have issued reports on CBIO shares. Zacks Investment Research downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Monday, June 5th. Chardan Capital started coverage on Catalyst Biosciences in a report on Monday, June 12th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Ladenburg Thalmann Financial Services started coverage on Catalyst Biosciences in a report on Tuesday, June 6th. They set a “buy” rating and a $11.00 price objective on the stock.
The stock has a 50 day moving average of $3.71 and a 200-day moving average of $4.89. The company’s market cap is $16.29 million.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.46) by $1.07. The business had revenue of $0.11 million for the quarter. Catalyst Biosciences had a negative return on equity of 178.44% and a negative net margin of 5,294.60%. Analysts expect that Catalyst Biosciences Inc will post ($7.08) earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zacks Investment Management acquired a new stake in shares of Catalyst Biosciences during the second quarter worth about $147,000. Dimensional Fund Advisors LP acquired a new stake in Catalyst Biosciences in the 2nd quarter valued at approximately $372,000. Virtu KCG Holdings LLC acquired a new stake in Catalyst Biosciences in the 2nd quarter valued at approximately $103,000. Vanguard Group Inc. raised its position in Catalyst Biosciences by 294.1% in the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 32,621 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Catalyst Biosciences in the 2nd quarter valued at approximately $107,000. 29.21% of the stock is currently owned by institutional investors.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.